Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 3 Results

Title
Intervention Indication Therapeutic Area Year Actions
Depatuxizumab mafodotin for newly diagnosed EGFR‐amplified glioblastoma – first line Depatuxizumab mafodotin (ABT-414) , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2018 View  |  Download
LAM-561 in addition to radiation therapy and temozolomide for glioblastoma –adjuvant 2-hydroxyoleic acid (2-OHOA; LP561A1; LAM561) , Radiotherapy , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2021 View  |  Download
Nivolumab in addition to temozolomide and radiotherapy for MGMT-methylated glioblastoma in newly diagnosed adults - first line Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications